DE69825906D1 - Verwendung von angiostatische steroide in photodynamischer therapie - Google Patents

Verwendung von angiostatische steroide in photodynamischer therapie

Info

Publication number
DE69825906D1
DE69825906D1 DE69825906T DE69825906T DE69825906D1 DE 69825906 D1 DE69825906 D1 DE 69825906D1 DE 69825906 T DE69825906 T DE 69825906T DE 69825906 T DE69825906 T DE 69825906T DE 69825906 D1 DE69825906 D1 DE 69825906D1
Authority
DE
Germany
Prior art keywords
photodynamic therapy
angiostatic steroids
angiostatic
steroids
steriod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825906T
Other languages
English (en)
Other versions
DE69825906T2 (de
Inventor
Abbot F Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Manufacturing Ltd filed Critical Alcon Manufacturing Ltd
Publication of DE69825906D1 publication Critical patent/DE69825906D1/de
Application granted granted Critical
Publication of DE69825906T2 publication Critical patent/DE69825906T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
DE69825906T 1997-07-16 1998-06-18 Verwendung von angiostatische steroide in photodynamischer therapie Expired - Fee Related DE69825906T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US895184 1997-07-16
US08/895,184 US5770592A (en) 1991-11-22 1997-07-16 Prevention and treatment of ocular neovascularization using angiostatic steroids
PCT/US1998/012711 WO1999003503A1 (en) 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy

Publications (2)

Publication Number Publication Date
DE69825906D1 true DE69825906D1 (de) 2004-09-30
DE69825906T2 DE69825906T2 (de) 2005-09-01

Family

ID=25404127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825906T Expired - Fee Related DE69825906T2 (de) 1997-07-16 1998-06-18 Verwendung von angiostatische steroide in photodynamischer therapie

Country Status (13)

Country Link
US (2) US5770592A (de)
EP (1) EP1003553B1 (de)
JP (1) JP2001510170A (de)
AT (1) ATE274356T1 (de)
AU (1) AU734195B2 (de)
BR (1) BR9811012A (de)
CA (1) CA2296558A1 (de)
DE (1) DE69825906T2 (de)
DK (1) DK1003553T3 (de)
ES (1) ES2224412T3 (de)
HK (1) HK1028952A1 (de)
PT (1) PT1003553E (de)
WO (1) WO1999003503A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1154691A4 (de) * 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Gezielte transsklerale gesteuerte wirkstoffabgabe an die retina und choroidae
EP1131099A2 (de) 1999-01-15 2001-09-12 Light Sciences Corporation Nichtinvasiven vaskulären therapie
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
JP2002534483A (ja) * 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション 代謝性骨障害または骨転移のための治療的組成物
DE60040876D1 (de) 1999-10-21 2009-01-02 Alcon Inc Medikamentenzuführeinrichtung
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ES2240180T3 (es) 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
ES2311507T3 (es) * 2000-02-10 2009-02-16 MASSACHUSETTS EYE & EAR INFIRMARY Terapia fotodinamica para tratamiento de afecciones oftalmicas.
EP1570859A3 (de) * 2000-03-24 2008-04-02 Novartis AG Verbesserte Behandlung von Neovaskularisation
UA75350C2 (en) 2000-03-24 2006-04-17 Novartis Ag Method for photodynamic treatment of undesirable subfoveal choroidal neovascularization using antiangiogenic agent
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
DE60131273T2 (de) * 2000-05-19 2008-08-28 Michael S. Beverly Hills Berlin Laserapplikationssystem und methode zur verwendung im auge
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
AU2002319606B2 (en) * 2001-07-23 2006-09-14 Alcon, Inc. Ophthalmic drug delivery device
PT1409065E (pt) 2001-07-23 2007-03-30 Alcon Inc Dispositivo de administração de fármacos oftálmicos
WO2003029268A1 (en) * 2001-10-03 2003-04-10 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
JP4468810B2 (ja) 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
AU2003259301A1 (en) * 2002-07-29 2004-02-16 Ast Products, Inc. Ophtalmic compositions
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
WO2004030588A2 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
EP1594511A2 (de) * 2003-02-20 2005-11-16 Alcon, Inc. Glucocorticoid-formulierungen zur behandlung von pathologischer angiogenese im auge
ZA200505989B (en) * 2003-02-20 2006-12-27 Alcon Inc Use the steroids to treat ocular disorders
KR20060019579A (ko) * 2003-06-13 2006-03-03 알콘, 인코퍼레이티드 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients
JP2007526019A (ja) * 2003-07-10 2007-09-13 アルコン，インコーポレイティド 眼科用薬物送達デバイス
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
WO2005072744A1 (ja) * 2004-02-02 2005-08-11 Yuichi Kaji 硝子体の可視化剤
CN1980929A (zh) * 2004-02-24 2007-06-13 比奥阿克松医疗技术股份有限公司 4－取代哌啶衍生物
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
CA2581126A1 (en) 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
EP2292672B1 (de) 2005-05-25 2018-05-09 CIS Pharma AG Bioverträgliche Polymere und Copolymere mit Aminosäuren in der Seitenkette
PL1919290T3 (pl) * 2005-07-12 2014-06-30 Ampio Pharmaceuticals Inc Sposoby i produkty do leczenia chorób
EP1909812A4 (de) 2005-07-27 2009-11-25 Univ Florida Kleine verbindungen zur korrektur von protein-missfaltungen und verwendungen davon
AU2006297571B2 (en) 2005-09-07 2012-03-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
CA2624837A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
JP5180834B2 (ja) 2005-11-29 2013-04-10 スミスクライン ビーチャム コーポレーション 治療方法
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8425449B2 (en) 2009-07-09 2013-04-23 Ivantis, Inc. Ocular implants and methods for delivering ocular implants into the eye
US20090181933A1 (en) * 2008-01-11 2009-07-16 Bingaman David P Use of steroids to treat persons suffering from ocular disorders
CA2717441A1 (en) 2008-03-05 2009-09-11 Ivantis, Inc. Methods and apparatus for treating glaucoma
EP3656385A1 (de) * 2008-05-28 2020-05-27 ReveraGen BioPharma, Inc. Nichthormonale steroide modulatoren von nf-kb zur behandlung von erkrankungen
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2010151531A1 (en) * 2009-06-22 2010-12-29 Dmi Acquistion Corp. Methods and products for treatment of diseases
SG176939A1 (en) * 2009-06-22 2012-01-30 Dmi Acquisition Corp Method for treatment of diseases
AU2010271274B2 (en) 2009-07-09 2015-05-21 Alcon Inc. Single operator device for delivering an ocular implant
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6126118B2 (ja) 2011-11-30 2017-05-10 ビカム ファーマスーティカルス，インコーポレイテッド オプシン結合性リガンド、組成物、及び使用方法
WO2013081642A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
CN108135470B (zh) 2015-08-14 2021-03-09 伊万提斯公司 具有压力传感器和输送系统的眼部植入物
WO2017106517A1 (en) 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
JP2024503989A (ja) 2021-01-11 2024-01-30 アルコン インコーポレイティド 粘弾性体送達のためのシステム及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
ATE190623T1 (de) * 1990-06-11 2000-04-15 Alcon Lab Inc Verwendung von steroiden zur inhibierung von angiogenesis
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
ES2224412T3 (es) 2005-03-01
CA2296558A1 (en) 1999-01-28
AU734195B2 (en) 2001-06-07
AU8151598A (en) 1999-02-10
US5770592A (en) 1998-06-23
WO1999003503A1 (en) 1999-01-28
ATE274356T1 (de) 2004-09-15
EP1003553B1 (de) 2004-08-25
PT1003553E (pt) 2004-10-29
BR9811012A (pt) 2000-10-17
HK1028952A1 (en) 2001-03-16
US6297228B1 (en) 2001-10-02
DE69825906T2 (de) 2005-09-01
DK1003553T3 (da) 2004-09-20
JP2001510170A (ja) 2001-07-31
EP1003553A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
ATE274356T1 (de) Verwendung von angiostatische steroide in photodynamischer therapie
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE59611341D1 (de) Verwendung von saccharid-konjugaten
DE69434491D1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
CY1106149T1 (el) Η χρηση ενωσεων υποκατεστημενης αζετιδινονης για την θepαπεια σιτοστepολαιμιας
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
TR199901003T2 (xx) Ast�m tedavisi i�in loratadin ve bir dekonjestan i�eren bile�im.
ATE202557T1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
ATE306270T1 (de) Verwendung von fulvestrant in der behandlung von resistentem brustkrebs
DE69710333T2 (de) Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie
DK1131073T3 (da) Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
TW200507858A (en) Formulations of glucocorticoids to treat pathologic ocular angiogenesis
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
BR9807980A (pt) Uso de um composto e composto para tratar um mamìfero com disfunção cognitiva
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
PT1169026E (pt) Utilizacao de activadores de ap-1 no tratamento do glaucoma e da hipertensao ocular

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee